ReviewInternational journal of colorectal disease2025

Clinical use of vedolizumab subcutaneous formulation in inflammatory bowel diseases: a review of real-world evidence.

Kirk B Russ et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.